Drug-induced steatohepatitis

References

• Farrell GC. Drugs and steatohepatitis. Semin Liver Dis. 2002;22:185–194.
   PubMed Web of Science ®Google Scholar
• Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274–285.
   PubMed Web of Science ®Google Scholar
• Grieco A, Forgione A, Miele L, et al. Fatty liver and drugs. Eur Rev Med Pharmacol Sci. 2005;9:261–263.
   PubMedGoogle Scholar
• Rabinowich L, Shibolet O. Drug induced steatohepatitis: an uncommon culprit of a common disease. Biomed Res Int. 2015;2015:168905.
   PubMed Web of Science ®Google Scholar
• Patel V, Sanyal AJ, Sterling R. Clinical presentation and patient evaluation in nonalcoholic fatty liver disease. Clin Liver Dis. 2016;20:277–292.
   PubMed Web of Science ®Google Scholar
• Begriche K, Massart J, Robin MA, et al. Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver. J Hepatol. 2011;54:773–794.
   PubMed Web of Science ®Google Scholar
• Schumacher JD, Guo GL. Mechanistic review of drug-induced steatohepatitis. Toxicol Appl Pharmacol. 2015;289:40–47.
   PubMed Web of Science ®Google Scholar
• Fong Y, Bentrem DJ. CASH (chemotherapy-associated steatohepatitis) costs. Ann Surg. 2006;243:8–9.
   PubMed Web of Science ®Google Scholar
• Wahlang B, Beier JI, Clair HB, et al. Toxicant-associated steatohepatitis. Toxicol Pathol. 2013;41:343–360.
   PubMed Web of Science ®Google Scholar
• Jaeschke H, Gores GJ, Cederbaum AI, et al. Mechanisms of hepatotoxicity. Toxicol Sci. 2002;65:166–176.
   PubMed Web of Science ®Google Scholar
• Kazmi F, Hensley T, Pope C, et al. Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells). Drug Metab Dispos. 2013;41:897–905.
   PubMed Web of Science ®Google Scholar
• Lowe R, Mussa HY, Nigsch F, et al. Predicting the mechanism of phospholipidosis. J Cheminform. 2012;4:2.
   PubMed Web of Science ®Google Scholar
• Shayman JA, Abe A. Drug induced phospholipidosis: an acquired lysosomal storage disorder. Biochim Biophys Acta. 2013;1831:602–611.
   PubMed Web of Science ®Google Scholar
• Amacher DE. The mechanistic basis for the induction of hepatic steatosis by xenobiotics. Expert Opin Drug Metab Toxicol. 2011;7:949–965.
   PubMed Web of Science ®Google Scholar
• Cole LK, Jacobs RL, Vance DE. Tamoxifen induces triacylglycerol accumulation in the mouse liver by activation of fatty acid synthesis. Hepatology. 2010;52:1258–1265.
   PubMed Web of Science ®Google Scholar
• Zhao F, Xie P, Jiang J, et al. The effect and mechanism of tamoxifen-induced hepatocyte steatosis in vitro. Int J Mol Sci. 2014;15:4019–4030.
   PubMed Web of Science ®Google Scholar
• Moya M, Gomez-Lechon MJ, Castell JV, et al. Enhanced steatosis by nuclear receptor ligands: a study in cultured human hepatocytes and hepatoma cells with a characterized nuclear receptor expression profile. Chem Biol Interact. 2010;184:376–387.
   PubMed Web of Science ®Google Scholar
• Amacher DE. Strategies for the early detection of drug-induced hepatic steatosis in preclinical drug safety evaluation studies. Toxicology. 2011;279:10–18.
   PubMed Web of Science ®Google Scholar
• Labbe G, Pessayre D, Fromenty B. Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies. Fundam Clin Pharmacol. 2008;22:335–353.
   PubMed Web of Science ®Google Scholar
• Kawano Y, Cohen DE. Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. J Gastroenterol. 2013;48:434–441.
   PubMed Web of Science ®Google Scholar
• Goldberg IJ, Eckel RH, Abumrad NA. Regulation of fatty acid uptake into tissues: lipoprotein lipase- and CD36-mediated pathways. J Lipid Res. 2009;50(Suppl):S86–90.
   PubMed Web of Science ®Google Scholar
• Thomson DM, Winder WW. AMP-activated protein kinase control of fat metabolism in skeletal muscle. Acta Physiol (Oxf). 2009;196:147–154.
   PubMed Web of Science ®Google Scholar
• Blas-Garcia A, Apostolova N, Ballesteros D, et al. Inhibition of mitochondrial function by efavirenz increases lipid content in hepatic cells. Hepatology. 2010;52:115–125.
   PubMed Web of Science ®Google Scholar
• Zhou J, Febbraio M, Wada T, et al. Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis. Gastroenterology. 2008;134:556–567.
   PubMed Web of Science ®Google Scholar
• Sahini N, Selvaraj S, Borlak J. Whole genome transcript profiling of drug induced steatosis in rats reveals a gene signature predictive of outcome. PLoS One. 2014;9:e114085.
   Google Scholar
• Benet M, Moya M, Donato MT, et al. A simple transcriptomic signature able to predict drug-induced hepatic steatosis. Arch Toxicol. 2014;88:967–982.
   PubMed Web of Science ®Google Scholar
• Liu Z, Wang Y, Borlak J, et al. Mechanistically linked serum miRNAs distinguish between drug induced and fatty liver disease of different grades. Sci Rep. 2016;6:23709.
   PubMed Web of Science ®Google Scholar
• Diehl AM. Lessons from animal models of NASH. Hepatol Res. 2005;33:138–144.
   PubMed Web of Science ®Google Scholar
• Kohli R, Feldstein AE. NASH animal models: are we there yet? J Hepatol. 2011;55:941–943.
   PubMed Web of Science ®Google Scholar
• Larter CZ, Yeh MM. Animal models of NASH: getting both pathology and metabolic context right. J Gastroenterol Hepatol. 2008;23:1635–1648.
   PubMed Web of Science ®Google Scholar
• London RM, George J. Pathogenesis of NASH: animal models. Clin Liver Dis. 2007;11:55–74, viii.
   PubMedGoogle Scholar
• Choi YJ, Lee CH, Lee KY, et al. Increased hepatic fatty acid uptake and esterification contribute to tetracycline-induced steatosis in mice. Toxicol Sci. 2015;145:273–282.
   PubMed Web of Science ®Google Scholar
• Larosche I, Letteron P, Fromenty B, et al. Tamoxifen inhibits topoisomerases, depletes mitochondrial DNA, and triggers steatosis in mouse liver. J Pharmacol Exp Ther. 2007;321:526–535.
   PubMed Web of Science ®Google Scholar
• Lelliott CJ, Lopez M, Curtis RK, et al. Transcript and metabolite analysis of the effects of tamoxifen in rat liver reveals inhibition of fatty acid synthesis in the presence of hepatic steatosis. Faseb J. 2005;19:1108–1119.
   PubMed Web of Science ®Google Scholar
• Gudbrandsen OA, Rost TH, Berge RK. Causes and prevention of tamoxifen-induced accumulation of triacylglycerol in rat liver. J Lipid Res. 2006;47:2223–2232.
   PubMed Web of Science ®Google Scholar
• Van Summeren A, Renes J, Lizarraga D, et al. Screening for drug-induced hepatotoxicity in primary mouse hepatocytes using acetaminophen, amiodarone, and cyclosporin a as model compounds: an omics-guided approach. Omics. 2013;17:71–83.
   PubMed Web of Science ®Google Scholar
• Le TT, Urasaki Y, Pizzorno G. Uridine prevents tamoxifen-induced liver lipid droplet accumulation. BMC Pharmacol Toxicol. 2014;15:27.
   PubMed Web of Science ®Google Scholar
• Deschamps D, DeBeco V, Fisch C, et al. Inhibition by perhexiline of oxidative phosphorylation and the beta-oxidation of fatty acids: possible role in pseudoalcoholic liver lesions. Hepatology. 1994;19:948–961.
   PubMed Web of Science ®Google Scholar
• Berson A, De Beco V, Letteron P, et al. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology. 1998;114:764–774.
   PubMed Web of Science ®Google Scholar
• Tong V, Teng XW, Chang TK, et al. Valproic acid II: effects on oxidative stress, mitochondrial membrane potential, and cytotoxicity in glutathione-depleted rat hepatocytes. Toxicol Sci. 2005;86:436–443.
   PubMed Web of Science ®Google Scholar
• Amacher DE, Martin BA. Tetracycline-induced steatosis in primary canine hepatocyte cultures. Fundam Appl Toxicol. 1997;40:256–263.
   PubMedGoogle Scholar
• Sassa S, Sugita O, Galbraith RA, et al. Drug metabolism by the human hepatoma cell, hep G2. Biochem Biophys Res Commun. 1987;143:52–57.
   PubMed Web of Science ®Google Scholar
• Choi JM, Oh SJ, Lee JY, et al. Prediction of drug-induced liver injury in hepG2 cells cultured with human liver microsomes. Chem Res Toxicol. 2015;28:872–885.
   PubMed Web of Science ®Google Scholar
• Cui W, Chen SL, Hu KQ. Quantification and mechanisms of oleic acid-induced steatosis in HepG2 cells. Am J Transl Res. 2010;2:95–104.
   PubMed Web of Science ®Google Scholar
• Donato MT, Martinez-Romero A, Jimenez N, et al. Cytometric analysis for drug-induced steatosis in HepG2 cells. Chem Biol Interact. 2009;181:417–423.
   PubMed Web of Science ®Google Scholar
• Kamalian L, Chadwick AE, Bayliss M, et al. The utility of HepG2 cells to identify direct mitochondrial dysfunction in the absence of cell death. Toxicol In Vitro. 2015;29:732–740.
   PubMed Web of Science ®Google Scholar
• Gerets HH, Tilmant K, Gerin B, et al. Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins. Cell Biol Toxicol. 2012;28:69–87.
   PubMed Web of Science ®Google Scholar
• Gripon P, Rumin S, Urban S, et al. Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci U S A. 2002;99:15655–15660.
   PubMed Web of Science ®Google Scholar
• Lambert CB, Spire C, Renaud MP, et al. Reproducible chemical-induced changes in gene expression profiles in human hepatoma HepaRG cells under various experimental conditions. Toxicol In Vitro. 2009;23:466–475.
   PubMed Web of Science ®Google Scholar
• Antherieu S, Chesne C, Li R, et al. Stable expression, activity, and inducibility of cytochromes P450 in differentiated HepaRG cells. Drug Metab Dispos. 2010;38:516–525.
   PubMed Web of Science ®Google Scholar
• Pant A, Kocarek T. Farnesol suppresses lipid accumulation in a HepaRG-based model of hepatic steatosis (1142.8). The FASEB Journal. 2014;28:1142.1148.
   Web of Science ®Google Scholar
• Rogue A, Antherieu S, Vluggens A, et al. PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells. Toxicol Appl Pharmacol. 2014;276:73–81.
   PubMed Web of Science ®Google Scholar
• Hannan NR, Segeritz CP, Touboul T, et al. Production of hepatocyte-like cells from human pluripotent stem cells. Nat Protoc. 2013;8:430–437.
   PubMed Web of Science ®Google Scholar
• Rashid ST, Corbineau S, Hannan N, et al. Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. J Clin Invest. 2010;120:3127–3136.
   PubMed Web of Science ®Google Scholar
• Sirenko O, Hesley J, Rusyn I, et al. High-content assays for hepatotoxicity using induced pluripotent stem cell-derived cells. Assay Drug Dev Technol. 2014;12:43–54.
   PubMed Web of Science ®Google Scholar
• Berger DR, Ware BR, Davidson MD, et al. Enhancing the functional maturity of induced pluripotent stem cell-derived human hepatocytes by controlled presentation of cell-cell interactions in vitro. Hepatology. 2015;61:1370–1381.
   PubMed Web of Science ®Google Scholar
• Yu Y, Liu H, Ikeda Y, et al. Hepatocyte-like cells differentiated from human induced pluripotent stem cells: relevance to cellular therapies. Stem Cell Res. 2012;9:196–207.
   PubMed Web of Science ®Google Scholar
• Wilkening S, Stahl F, Bader A. Comparison of primary human hepatocytes and hepatoma cell line Hepg2 with regard to their biotransformation properties. Drug Metab Dispos. 2003;31:1035–1042.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Antona C, Donato MT, Boobis A, et al. Cytochrome P450 expression in human hepatocytes and hepatoma cell lines: molecular mechanisms that determine lower expression in cultured cells. Xenobiotica. 2002;32:505–520.
   PubMed Web of Science ®Google Scholar
• Baker TK, Carfagna MA, Gao H, et al. Temporal gene expression analysis of monolayer cultured rat hepatocytes. Chem Res Toxicol. 2001;14:1218–1231.
   PubMed Web of Science ®Google Scholar
• Boess F, Kamber M, Romer S, et al. Gene expression in two hepatic cell lines, cultured primary hepatocytes, and liver slices compared to the in vivo liver gene expression in rats: possible implications for toxicogenomics use of in vitro systems. Toxicol Sci. 2003;73:386–402.
   PubMed Web of Science ®Google Scholar
• Suckale J, Solimena M. Pancreas islets in metabolic signaling–focus on the beta-cell. Front Biosci. 2008;13:7156–7171.
   PubMed Web of Science ®Google Scholar
• Bertrand F, Philippe C, Antoine PJ, et al. Insulin activates nuclear factor kappa B in mammalian cells through a Raf-1-mediated pathway. J Biol Chem. 1995;270:24435–24441.
   PubMed Web of Science ®Google Scholar
• Cai D, Yuan M, Frantz DF, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med. 2005;11:183–190.
   PubMed Web of Science ®Google Scholar
• Ke B, Zhao Z, Ye X, et al. Inactivation of NF-kappaB p65 (RelA) in liver improves insulin sensitivity and inhibits cAMP/PKA pathway. Diabetes. 2015;64:3355–3362.
   PubMed Web of Science ®Google Scholar
• Dash A, Inman W, Hoffmaster K, et al. Liver tissue engineering in the evaluation of drug safety. Expert Opin Drug Metab Toxicol. 2009;5:1159–1174.
   PubMed Web of Science ®Google Scholar
• Kane BJ, Zinner MJ, Yarmush ML, et al. Liver-specific functional studies in a microfluidic array of primary mammalian hepatocytes. Anal Chem. 2006;78:4291–4298.
   PubMed Web of Science ®Google Scholar
• Xia L, Ng S, Han R, et al. Laminar-flow immediate-overlay hepatocyte sandwich perfusion system for drug hepatotoxicity testing. Biomaterials. 2009;30:5927–5936.
   PubMed Web of Science ®Google Scholar
• Domansky K, Inman W, Serdy J, et al. Perfused multiwell plate for 3D liver tissue engineering. Lab Chip. 2010;10:51–58.
   PubMed Web of Science ®Google Scholar
• Hastings NE, Simmers MB, McDonald OG, et al. Atherosclerosis-prone hemodynamics differentially regulates endothelial and smooth muscle cell phenotypes and promotes pro-inflammatory priming. Am J Physiol Cell Physiol. 2007;293:C1824–1833.
   PubMed Web of Science ®Google Scholar
• Dash A, Simmers MB, Deering TG, et al. Hemodynamic flow improves rat hepatocyte morphology, function, and metabolic activity in vitro. Am J Physiol Cell Physiol. 2013;304:C1053- C1063.
   PubMed Web of Science ®Google Scholar
• Dash A, Deering TG, Marukian S, et al., Human primary hepatocytes under controlled hemodynamics elicit induction responses to drugs at clinical cmax concentrations, 52nd Annual Meeting of the Society of ToxicologySan Antonio, Texas., 2013, pp. 10.
   Google Scholar
• Dash A, Deering T, Marukian S et al. Physiological Hemodynamics and Transport Restore Insulin and Glucagon Responses in a Normal Glucose Milieu in Hepatocytes in Vitro. (2013) In late breaking ADA abstracts. Diabetes Vol 62 (Suppl. 1A) pLB37
   Google Scholar
• Deering TG, Thomas JT, Blackman BR, Wamhoff BR, Dash A. Development of an in vitro model of hepatic steatosis using rat hepatocytes under controlled hemodynamics in a diabetic milieu. (2012), In AASLD Abstracts. Hepatology, Vol 56: p868A.
   Google Scholar
• Terelius Y, Figler RA, Marukian S, et al. Transcriptional profiling suggests that nevirapine and ritonavir cause drug induced liver injury through distinct mechanisms in primary human hepatocytes. Chem Biol Interact. 2016 Aug 5;255:31–44.
   PubMed Web of Science ®Google Scholar
• Reeder SB, Hu HH, Sirlin CB. Proton density fat-fraction: a standardized MR-based biomarker of tissue fat concentration. J Magn Reson Imaging. 2012;36:1011–1014.
   PubMed Web of Science ®Google Scholar
• Sasso M, Audiere S, Kemgang A, et al. Liver steatosis assessed by Controlled Attenuation Parameter (CAP) measured with the xl probe of the fibroscan: a pilot study assessing diagnostic accuracy. Ultrasound Med Biol. 2016;42:92–103.
   PubMed Web of Science ®Google Scholar
• Sasso M, Miette V, Sandrin L, et al. The controlled attenuation parameter (CAP): a novel tool for the non-invasive evaluation of steatosis using Fibroscan. Clin Res Hepatol Gastroenterol. 2012;36:13–20.
   PubMed Web of Science ®Google Scholar
• Deffieux T, Gennisson JL, Bousquet L, et al. Investigating liver stiffness and viscosity for fibrosis, steatosis and activity staging using shear wave elastography. J Hepatol. 2015;62:317–324.
   PubMed Web of Science ®Google Scholar
• Eddowes P, Sasso M, Fournier C, et al. Steatosis and liver stiffness measurements using transient elastography. Hepatology. 2016;64:700-700.
   PubMed Web of Science ®Google Scholar
• Macaluso FS, Maida M, Camma C, et al. Steatosis affects the performance of liver stiffness measurement for fibrosis assessment in patients with genotype 1 chronic hepatitis C. J Hepatol. 2014;61:523–529.
   PubMed Web of Science ®Google Scholar
• Ballestri S, Nascimbeni F, Romagnoli D, et al. The independent predictors of NASH and its individual histological features. Insulin resistance, serum uric acid, metabolic syndrome, ALT and serum total cholesterol are a clue to pathogenesis and candidate targets for treatment. Hepatol Res. 2016;46:1074–1087.
   PubMed Web of Science ®Google Scholar
• Torres DM, Harrison SA. NAFLD: predictive value of ALT levels for NASH and advanced fibrosis. Nat Rev Gastroenterol Hepatol. 2013;10:510–511.
   PubMed Web of Science ®Google Scholar
• Harnois F, Msika S, Sabate JM, et al. Prevalence and predictive factors of non-alcoholic steatohepatitis (NASH) in morbidly obese patients undergoing bariatric surgery. Obes Surg. 2006;16:183–188.
   PubMed Web of Science ®Google Scholar
• Losekann A, Weston AC, De Mattos AA, et al. Non-Alcoholic Steatohepatitis (NASH): risk factors in morbidly obese patients. Int J Mol Sci. 2015;16:25552–25559.
   PubMed Web of Science ®Google Scholar
• Fisher CD, Lickteig AJ, Augustine LM, et al. Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. Drug Metab Dispos. 2009;37:2087–2094.
   PubMed Web of Science ®Google Scholar
• Lake AD, Novak P, Fisher CD, et al. Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease. Drug Metab Dispos. 2011;39:1954–1960.
   PubMed Web of Science ®Google Scholar
• Chtioui H, Semela D, Ledermann M, et al. Expression and activity of the cytochrome P450 2E1 in patients with nonalcoholic steatosis and steatohepatitis. Liver Int. 2007;27:764–771.
   PubMed Web of Science ®Google Scholar
• Schattenberg JM, Czaja MJ. Regulation of the effects of CYP2E1-induced oxidative stress by JNK signaling. Redox Biol. 2014;3:7–15.
   PubMed Web of Science ®Google Scholar
• Hardwick RN, Clarke JD, Lake AD, et al. Increased susceptibility to methotrexate-induced toxicity in nonalcoholic steatohepatitis. Toxicol Sci. 2014;142:45–55.
   PubMed Web of Science ®Google Scholar
• Ijssennagger N, Janssen AW, Milona A, et al. Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid. J Hepatol. 2016;64:1158–1166.
   PubMed Web of Science ®Google Scholar
• Ding X, Thung SN, Grewal P. Steatohepatitis secondary to long-term glucocorticoid treatment for congenital adrenal hyperplasia: a potential diagnostic pitfall. Semin Liver Dis. 2013;33:389–392.
   PubMed Web of Science ®Google Scholar
• He J, Li G, Chen J, et al. Prolonged exposure to low-dose microcystin induces nonalcoholic steatohepatitis in mice: a systems toxicology study. Arch Toxicol. (2016). doi:10.1007/s00204-016-1681-3
   Google Scholar